Company intelligence / Profile preview

Zhejiang Jolly Pharmaceutical

Hangzhou, Zhejiang, Chinajollypharmaindia.com ↗

Ownership: Private
Development stage: Other

Overview

Jolly has a broad portfolio of over 100 generic drugs and APIs. Several proprietary/herbal medicines are approved in China. Pipeline includes late-stage clinical programs such as Polycarbophil Calcium (Phase 3) and Lingxiang Tablets (Phase 2). The company emphasizes R&D investment (~8–10% of revenue), supporting both domestic sales (~60%) and international exports (~40%). No recent major global clinical trial results reported publicly.

Therapeutic areas: NeurologyPsychiatryWomen's HealthPulmonologyMen's HealthGastroenterologyEndocrinologyCardiovascular
Modalities: Small moleculeHerbal medicinePolymer-based drugs
Industry: Biotech

Partnerships

Medical services at Deqing No. 3 People’s HospitalInternational distribution/export markets

Beyond the preview

Go deeper on Zhejiang Jolly Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhejiang Jolly Pharmaceutical.

Explore the full profile